Introduction: The aim of our study was to evaluate the significance of transurethral resection of the prostate (TURP) to detect prostate cancer (PCa). A comparison was performed of the TURP specimens of patients undergoing high-intensity focused ultrasound (HIFU) with the core biopsies. Materials and Methods: TURP before undergoing HIFU therapy was performed in 106 patients without neoadjuvant treatment. The resected tissue was subjected to histopathological evaluation and compared to the histological results of transrectal prostate biopsy. Results: Cancer was detected in the resected tissue of 69 patients (65%). A positive correlation of the amount of resected tissue and detection of PCa could be demonstrated in a multivariate analysis. Conclusions: With a rate of 65% PCa detected by TURP, our data provide evidence that TURP might be suitable to detect PCa in a small group of selected patients with continuously rising PSA levels and several negative biopsies. On the other hand, these data underline/reinforce the necessity to treat the whole gland using modern treatment modalities such as HIFU and cryotherapy.

1.
Hodge KK, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound-guided transrectal core biopsies of the prostate. J Urol 1989;142:71-74.
2.
Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-1574.
3.
Djavan B, Mazal P, Zlotta A, et al: Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection Study. Prostate 2001;47:111-117.
4.
Pacelli A, Bostwick DG: Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997;50:355-359.
5.
Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004;171:2265-2267.
6.
Van der Kwast TH, Lopes C, Santonja C, et al: Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003;56:336-340.
7.
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
8.
Kawakami S, Okuno T, Yonese J, et al: Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol 2007;51:675-682.
9.
Ornstein DK, Rao GS, Smith DS, Andriole GL: The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997;157:880-883.
10.
Merrill RM, Wiggins CL: Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 2002;7:213-219.
11.
Niesel T, Breul J, Hartung R: Diagnostic value of additional systematic prostate biopsies in patients undergoing transurethral resection of the prostate. Urology 1997;49:869-873.
12.
Zigeuner R, Schips L, Lipsky K, et al: Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 2003;62:883-887.
13.
Bratt O: The difficult case in prostate cancer diagnosis - when is a ‘diagnostic TURP' indicated? Eur Urol 2006;49:769-771.
14.
Kitamura H, Masumori N, Tanuma Y, et al: Does transurethral resection of the prostate facilitate detection of clinically significant prostate cancer that is missed with systematic sextant and transition zone biopsies? Int J Urol 2002;9:95-99.
15.
Epstein JI, Walsh PC, Carter HB: Importance of posterolateral needle biopsies in the detection of prostate cancer. Urology 2001;57:1112-1116.
16.
Stewart CS, Leibovich BC, Weaver AL, Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166: 86-91.
17.
Barzell WE, Melamed MR: Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal three-dimensional pathologic mapping of the prostate - a 4-year experience. Urology 2008;70(suppl):27-35.
18.
Smeenge M, Barentsz J, Cosgrove D, et al: Role of transrectal ultrasonography in focal therapy of prostate cancer: report from a consensus panel. BJU Int 2012;110:942-948.
19.
Salomon G, Spethmann J, Beckmann A, et al: Accuracy of HistoScanning™ for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int 2013;111:60-66.
20.
Dickinson L, Ahmed HU, Allen C, et al: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477-494.
21.
Heung YM, Walsh K, Sriprasad S, Mulvin D, Sherwood RA: The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int 2000;85:65-69.
22.
Moreno JG, O'Hara SM, Long JP, et al: Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR. Urology 1997;49:515-520.
23.
Ogawa O, Iinuma M, Sato K, et al: Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy. Urol Res 1999;27:291-296.
24.
Kunz GM Jr, Epstein JI: Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 2003;34:911-914.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.